Scholar Rock (SRRK)
Develops anti-myostatin antibodies for spinal muscular atrophy and other neuromuscular diseases.
Something off on this page? Send us feedback.
Develops selective antibody therapies for spinal muscular atrophy and other rare neuromuscular diseases, led by the investigational myostatin inhibitor apitegromab. With no approved products or product sales, the business depends on regulatory clearance, launch execution, and third-party manufacturing.
Develops antibody medicines that selectively block activation of latent growth factors, with a strategic focus on rare neuromuscular diseases. Apitegromab, an investigational myostatin inhibitor, has completed a successful pivotal study in spinal muscular atrophy and is under U.S. and European regulatory review. Studies in younger SMA patients and facioscapulohumeral muscular dystrophy, a subcutaneous apitegromab formulation, and SRK-439 extend the anti-myostatin pipeline.
Prepares for potential launches in the United States and Europe while seeking partners for oncology, fibrosis, anemia, and weight-loss combination programs. No product has been approved or generated product sales. Commercialization depends on regulatory clearance, reimbursement, and third-party manufacturing; following an adverse inspection classification at the original fill-finish provider, the U.S. application is proceeding with an alternate facility.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 21, 2026 | Cantor Fitzgerald | Reiterate | Rating: —Target: — | Target: $70 |
| Sep 15, 2026 | Evercore ISI | Reiterate | Rating: —Target: — | Target: $72 |
| Sep 15, 2026 | Wedbush | Reiterate | Rating: —Target: $64 | Target: $70 |
| Sep 15, 2026 | Piper Sandler | Reiterate | Rating: —Target: $58 | Target: $75 |
| Sep 15, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $65 | Target: $70 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $492.1M · Total debt $203.8M · Total assets $523.5M · Shareholders' equity $253.8M
- Revenue
- $0
- Operating income
- −$108.9M
- Net income
- −$109.9M
No dividends on record.
| Institutions | 114.62% | 139.59M shares | |
|---|---|---|---|
| 317 holders · as of Jun 30, 2026 | |||
| Insiders | 9.96% | 12.13M shares | |
| 20 holders · as of Jul 6, 2026 | |||
| Strategic holders | 8.89% | 10.83M shares | |
| 1 holder · as of Feb 6, 2026 | |||
| Adds to | 133.47% | ||
121.79M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 133.47%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 14.78% | 18.00M | as of Jun 30, 2026 |
Invus Global Management, LLCStrategic10 percent owner | 8.89% | 10.83M | filed Feb 6, 2026 |
Siren, L.L.C.Institution | 7.86% | 9.58M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 7.80% | 9.49M | as of Jun 30, 2026 |
Srinivas AkkarajuInsider | 5.74% | 6.99M | filed Oct 7, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 1, 2026 | Katie Peng | director | −5,446 | $53.88 |
| Jul 1, 2026 | Joshua Reed | director | −3,053 | $53.74 |
| Jul 1, 2026 | Kristina Burow | director | −3,053 | $53.74 |
| Jul 1, 2026 | Michael Gilman | director | −2,544 | $53.87 |
| Jul 1, 2026 | Jeffrey S. Flier | director | −3,053 | $53.88 |
- Biogen
Intrathecal SMA incumbent with next-generation ASO follow-on
- Novartis (ADR)
Gene-therapy SMA incumbent with acquired FSHD RNA pipeline
- Dyne Therapeutics
FSHD DUX4-silencing pipeline peer in neuromuscular disease
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Scholar Rock | $50.81 | +5.50% | $5.77B | — | — | — | — |
| Biogen | $225.27 | +2.83% | $32.37B | 38.8 | 17.0 | 3.3 | +3.4% |
| Novartis (ADR) | $141.28 | +0.21% | $267.96B | 21.3 | 15.0 | 4.8 | +0.9% |
| Dyne Therapeutics | $17.40 | +1.61% | $3.20B | — | — | — | — |
| Median | 30.0 | 16.0 | 4.0 | +2.2% |